{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:53:27Z","timestamp":1791114807735,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,2,5]],"date-time":"2002-02-05T00:00:00Z","timestamp":1012867200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Polymyositis is a rare inflammatory muscular disease of unknown cause. Corticosteroids and immunosuppressive drugs are the first choice of therapy but are not always effective and may cause serious side effects. Many studies have shown that polyvalent intravenous immunoglobulin (IVIG) may be of interest for the treatment of dermatomyositis. We carried out an open, prospective study to evaluate the efficacy of IVIG in subjects with polymyositis that was refractory to traditional treatments, and we evaluated the benefits of this therapy over a long\u2010term period of followup.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty\u2010five adult white patients (20 female, 15 male, mean age 43.5 years [SD 16.8]) with chronic, refractory polymyositis were treated with high doses of IVIG, after the patients had received the following traditional treatments: prednisone (n = 35), methotrexate (n = 24), azathioprine (n = 13), cyclophosphamide (n = 4), cyclosporine (n = 7), chlorambucil (n = 1), plasmapheresis (n = 8), lymphopheresis (n = 1), and total body irradiation (n = 1). There had been no changes in the patients' treatment in the 2 months before the initiation of IVIG therapy, and doses were not increased during IVIG treatment. We used preparations of polyvalent human IVIG with increased concentrations of intact IgG. The patients received 1 gm\/kg\/day for 2 consecutive days per month. The mean course of treatment was 4\u20136 months. The clinical assessment involved the evaluation of proximal muscle power, muscle disability scale score, and esophageal disorders. The biochemical evaluations carried out before each treatment period were compared by Student's <jats:italic>t<\/jats:italic>\u2010test and nonparametric Wilcoxon test. Results were considered to be significant at <jats:italic>P<\/jats:italic> = 0.05.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the short\u2010term, significant clinical improvement was noted in 25 of the 35 patients (71.4%). Mean muscle power was estimated before and after IVIG therapy and was found to be significantly improved (<jats:italic>P<\/jats:italic> &lt; 0.01). All patients had a significant biochemical response. Mean creatine kinase levels during IVIG therapy decreased significantly before the fourth IVIG perfusion (<jats:italic>P<\/jats:italic> &lt; 0.01). Side effects, usually minor, were noted in 6 patients. This benefit allowed the initial prednisone dose to be reduced by &gt;50% in all patients. The mean (\u00b1SD) followup time for the 25 patients who responded favorably to IVIG treatment was 51.4 \u00b1 13.1 months. Twelve of these 25 patients remained in full remission following their initial course of IVIG, resulting in complete stoppage of medication in 5 patients or low doses of steroids in 7 patients. The condition of 6 patients remained improved and no other drugs were prescribed, but the patients remained dependent on IVIG infusions. Seven of the 25 patients who responded well to IVIG treatment relapsed at an average of 17.1 months (range 4\u201323 months) after the discontinuation of IVIG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IVIG is an interesting therapy for the treatment of polymyositis, with results showing that the condition of \u223c70% of the patients tested improved. After the discontinuation of the IVIG therapy, the efficacy remained stable in 50% of the patients, with a followup of over 3 years.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.10053","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T22:20:15Z","timestamp":1030314015000},"page":"467-474","source":"Crossref","is-referenced-by-count":204,"title":["Results and long\u2010term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty\u2010five adult patients"],"prefix":"10.1002","volume":"46","author":[{"given":"P.","family":"Cherin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Laforet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Genereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Herson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,2,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252107"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(86)80180-0"},{"key":"e_1_2_5_4_2","first-page":"1135","article-title":"Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme\u2010B genes and the protein TIA\u20101 in muscle biopsies of myositis","volume":"23","author":"Cherin P","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197202172860701"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602063140601"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199754010-00003"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199911000-00003"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91630-S"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90009-M"},{"key":"e_1_2_5_11_2","first-page":"1979","article-title":"[Intravenously\u2010administered immunoglobulins as first\u2010choice agent in juvenile dermatomyositis]","volume":"137","author":"Breems DA","year":"1993","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_5_12_2","first-page":"148","article-title":"Dermatomyositis in a patient under chronic hemodialysis: treatment with intravenous immunoglobulins","volume":"145","author":"Finielz P","year":"1994","journal-title":"Ann Med Interne (Paris)"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405123301918"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.Suppl.50"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0887-8994(95)00195-6"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02230347"},{"key":"e_1_2_5_17_2","first-page":"111","article-title":"Intravenous immunoglobulin therapy in juvenile dermatomyositis","volume":"38","author":"Tsai MJ","year":"1997","journal-title":"Zhonghua Min Guoxiao Er Ke Yi Xue Hui Za Zh."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.37.642"},{"key":"e_1_2_5_19_2","first-page":"89","article-title":"Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin","volume":"62","author":"Peake MF","year":"1998","journal-title":"Cutis"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-200x.1999.01132.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1999.tb02026.x"},{"key":"e_1_2_5_22_2","first-page":"29","article-title":"High dose intravenous immunoglobulin (IVIg) in dermatomyositis: clinical responses and effect on sIL\u20102R levels","volume":"10","author":"Gottfried I","year":"2000","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4823"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292704"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380123"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117520"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90699-C"},{"key":"e_1_2_5_29_2","volume-title":"Aids to the investigation of peripheral nerve injuries","author":"British Medical Research Council","year":"1943"},{"key":"e_1_2_5_30_2","first-page":"1092","article-title":"Intravenous gammaglobulin as first line therapy in polymyositis and dermatomyositis: a report of 11 cases","volume":"21","author":"Cherin P","year":"1994","journal-title":"J Rheumatol"},{"issue":"9","key":"e_1_2_5_31_2","first-page":"S168","article-title":"Evaluation of muscle disability in adult polymyositis and dermatomyositis with a functional assessment score","volume":"38","author":"Herson S","year":"1995","journal-title":"Arthritis Rheum"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901213400311"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199111000-00002"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(200003)23:3<385::AID-MUS10>3.0.CO;2-T"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.1.65"},{"key":"e_1_2_5_36_2","first-page":"471","article-title":"Cytokines in the muscle tissue of idiopathic inflammatory myopathies: implications for immunopathogenesis and therapy","volume":"10","author":"Megens\u2010de Letter MA","year":"1999","journal-title":"Eur Cytokine Netw"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.38.632"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65141-3"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/59.2.164"},{"key":"e_1_2_5_40_2","first-page":"940","article-title":"Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis","volume":"27","author":"Nyberg P","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.10.5459"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199812)21:12<1668::AID-MUS7>3.0.CO;2-#"},{"key":"e_1_2_5_43_2","first-page":"1641","article-title":"Relapse of polymyositis after prolonged remission","volume":"24","author":"Lee W","year":"1997","journal-title":"J Rheumatol"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.10053","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.10053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:05:37Z","timestamp":1698714337000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.10053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1002\/art.10053"],"URL":"https:\/\/doi.org\/10.1002\/art.10053","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}